

CURICULAM-VITAE

Professional Objective: Consultant Hematology and Medical Oncology

1. NAME: **Shyam** **Aggarwal**
 First Name Last Name

2. EDUCATION QUALIFICATION:

Institution (Location)	Degree	Year Conferred	Field of Study
Medical College (Rohtak)	M.B.B.S.	1981	Medicine & surgery
PGIMER. (Chandigarh)	M. D.	1984	Medicine
Medical Registration Number	159		Haryana Medical Council

3. RESEARCH/ TRAINING EXPERIENCE: 26 YEARS

Year	Duration	Institution	Particular of work done
1997-Till Now	120months	Sir Ganga Ram Hospital Old Rajinder Nagar New Delhi 110060	Chairman-Dept. of Oncology Medical & Hematology Oncology Stem cell Transplantation
1991-96	72 months	Mool Chand K.R. Hospital	Consultant. Medical Oncology
1989-90	14 months	UCLA, Los Angeles	Clinical bone marrow Transplantation Molecular biology of Haematopoietic Growth factors and their Receptors
1988	2 months	St. Vincents Hospital	Clinical bone marrow Transplantation
1986	1-week	University of Ulm, Germany	Clinical Bone marrow transplantation

1985-89	39 months	Medical Oncology division Institute Rotary Cancer Hospital, AIIMS	Experimental fetal liver haematopoietic stem cell transplants in rhesus Monkeys Clinical research trials in Hematological & solid tumor Malignancies
1982	6 months	Blood Bank, PGIMER Chandigarh	Basics of blood banking
1981-84	36 months	Dept.Of Medicine PGIMER, Chandigarh	Training in Internal medicine

4. HONOURS & SCHOLARSHIPS:

- a. Awarded NIH – International Fogarty Fellowship for training in the field of bone marrow transplantation and basics medical research at UCLA. Los Angeles, USA.
- b. Silver Medal for standing first in M.D. Internal Medicine.
- c. Silver Medal for standing first in Medicine in M.B.B.S. Final.
- d. Selected in National Talent Search scheme by ICMR and awarded senior research fellowship after M.B.B.S.

5. PUBLICATIONS:

- I. Fetal liver infusion in acute myelogenous leukemia Kochupillai V, Sharma S, Francis S, Nanu A. IC. Dua H.K., Kumar L. K., Aggarwal S, Singh S, Thymus 10 117, **1987**.
- II. Fetal liver infusion in aplastic anemia Kochupillai V, Sharma S, Francis S, Nanu \ Suman M, Bhatia P., Dua H.K, Aggarwal S, Singh S, Kumar S, Karak A, Bhargawa M. Thymus 1089, **1987**.
- III. Ocular toxicity of low dose Cytosar Kumar L. Dua H. K., Aggarwal S, Singh S, Kochupillai V. The New Zealand Journal of Medicine 100 36. **1987**.

- IV. Fetal liver transplantation in rhesus monkeys. Aggarwal S, Sharma DN, Chatterji B, Sharma S, Narayan N, Rath GK, Dawar R, Kochupillai V. Transplantation Proceedings 21 (I): 3114. **1989**.
- V. Phycomycosis in acute leukemia. Kumar L, Singh S, Aggarwal S, Mathur M, Bijlani L, Kochupillai V. J. Asso Phys India 38 787, **1990**.
- VI. Haemopoietic stem cell differentiation in fetal liver spleen and thymus in rhesus monkeys Sharma S, Sharma DN, Aggarwal S, Medical Oncology and Tumor Pharmacology
- VII. Haemopoietic growth factors – Biology and Clinical Promise. Aggarwal S. National Medical Journal of India 4: 282. **1991**.
- VIII. Role of combined modality treatment in advanced squamous carcinoma of maxillary sinus. Femandes PS., Aggarwal S., Bahadur S., Indian Journal of Otolaryngology. 42:154. **1990**
- IX. Role of refrigerated autologous peripheral blood infusion following high dose chemotherapy Transplantation proceedings (In Press) Aggarwal S, Singh B, et al.
- X. Rapid recovery of hematopoiesis in patients given high – dose chemotherapy followed by infusion of refrigerated unprocessed autologous bone marrow and peripheral blood Aggarwal S, Singh B, Sood SK, Kurma VP, Byotra SP, Sachar VP, Saran RK. Transplant Proc. **2000** Nov; 32 (7): 2460-1
- XI. Advances in the Chemotherapy of Metastatic Colo- Rectal Cancer: Review article; Shyam Aggarwal, Charanjeev S Kapoor; Journal International Medical Sciences Academy Vol.16 No. 2, April to June **2003**, Pages 98 to 102.
- XII. Targeted therapy of cancer; Charanjeev S Kapoor, Shyam Aggarwal Journal International Medical Sciences Academy Vol.16 No. 2, April to June **2003**.
- XIII. Successful Mangement of Tumor Lysis Syndrome in Burkitt's Lymphoma; Shyam Aggarwal, C.S.Kapoor, Neeraj Jain, Indian Journal of Medical & Paediatric Oncology, Vol. 26, No.1, **2005**.
- XIV. Treatment of idiopathic hyperepsinophilic syndrome with imatinib mesylate. A Garg ,L Duggal, S Aggarwal , N Jain , accepted for publication in JAPI **2006**:54:883-6

- XV. Clinical experience with gefitinib (IRESSA) in Indian patients. Purvish Parikh MD, Alex Yuang-chi Chang BM, Shona Nag MD, Raghunadharao Digumarti MD, Dinesh Chandra Doval MD, Govind Babu MD, Raju Titus Chacko MD, Suresh Adani MD , Anantbhushan Ranade MD, Shyam Aggarwal MD ,Ramesh Jagannathan MD, Laura Hargreaves MSc, Nick Thatcher Phd . Accepted for publication in Journal of Thoracic Oncology **2008**.
- XVI. Role of recombinant Erythropoietinin Anemia due to cancer chemotherapy accepted for publication in IJMR **2008**.

6. ABSTRACTS PUBLISHED:

1. Presented a paper entitled- Efficacy of Cisplatin, Ifosfamide and Etoposide in advanced Non- Small Cell lung cancer in Asia pacific cancer conference held in Penang Malaysia in **1995**.
2. Presented a paper entitled - Rapid recovery of hematopoiesis in patients given high – dose chemotherapy followed by infusion of refrigerated unprocessed autologous bone marrow and peripheral blood. In CAST meeting held in Singapore **1999**.
3. Presented a paper entitled – Cure in a patient with primary Hodgkin's Lymphoma of liver, at Indian society of Medical & Pediatric Oncology meeting held in Jodhpur **2000**.
4. Presented a paper entitled – Efficacy of paclitaxel, irinotecan and carboplatin in patients with advanced non-small cell lung cancer. At ASCO **2002** held in Orlando.
5. Presented a paper entitled – Efficacy of oxaliplatin, 5FU, Gemcitabine, Leucovorin in patients with advanced pancreatic cancers. At ASCO **2003** held in Chicago.
6. Presented a paper entitled – Efficacy of capecitabine in advanced breast cancer. At SAARC Oncology Conference in **2004** in Katmandu, Nepal.
7. Central nervous toxicity of gefitinib in adult. Lung Cancer **2005**; 49.
8. Presented a paper entitled – Efficacy of oxaliplatin, 5 FU and gemcitabine in advance pancreato- biliary cancer in ASCO **2007**.

7. Guide for DNB:

Topic: Incremental value of PET-CT in the evaluation of colorectal malignancies recurrences. By Dr. Swagat Dash dept. of Nuclear medicine

Topic: Study of incidence and type of pleural effusion. By Dr. Kiran Dept. of Medicine

Topic: Diagnosis of Invasive Aspergillosis by using Galactomannan Assay in High risk Patients. By Dr. Shilpi S. Khanna Dept. of Microbiology

8. RETROSPECTIVE / PROSPECTIVE STUDIES ON CANCER:

The titles of these studies are as follows –

- 1) Role of combination chemotherapy in Advanced Biliary and Pancreatic Cancer (oxaliplatin +gemcitabine +5-FU).
- 2) Role of combination chemotherapy in Advanced Stomach Cancer (Oxaliplatin +docetaxel + capecitabine) .
- 3) Role of combination chemotherapy in Advanced Ovarian Cancer (Oxaliplatin +gemcitabine) .
- 4) Analysis of CML-CP patients in Imatinib up front.
- 5) Results of R-CHOP treatment in NHL.

9. Research Projects:

- Efficacy of Autologous peripheral blood stem cell transplant in Imatinib failed CML in chronic phase submitted to DBT for approval.
- Mutation analysis in CML patients on Imatinib.

10. Clinical Trials:

Principal Investigator in following Clinical Trials

1. Study Protocol: IPL – IBT- P03 – 03 – A: An Evaluation of Safety and Efficacy of recombinant Erythropoietin (EPO) (IPL- P03) in patients with Cancer – Related Anemia. A Prospective, Non – comparative, Open Label, Multicenter Study.(14 enrollments)
2. Protocol: MO18024- Study Title: First – line Bevacizumab & chemotherapy in Metastatic Cancer of the colon or Rectum. An Expanded Access Program. (4 enrollments)
3. Working on Multicenter prospective open- label study of role of interleukin –2 in Metastatic Renal cell cancer (by Credence)-1 enrollments)
4. Working on role of Glufosfamide in Gemcitabine treated patients with Metastatic Pancreatic Cancer – a Phase III study (by Threshold)-0 enrollments)
5. An observational study, Multicenter study on the impact of therapeutic decision making for medicinal naïve patients with newly diagnosed neuroendocrine GEP tumors intent to receive Sandostatin LAR treatment under condition of normal clinical practice
6. STUDY CODE D4200C00057- A phase III Randomised, Double-Blind, Multi –Centre, Parallel-Group Study to assess the efficacy of ZD6474(ZACTIMA) Versus Erlotinib (TARCEVA) in patients with Locally /Advanced or Metastatic (STAGE IIIB –IV) Non –Small cell lung cancer (NSCLC) after failure of at least one prior Cytotoxic Chemotherapy(AstraZeneca)-6 enrollments
7. Study Protocol: EDF 104383 Study: A Randomized Double Blind, Placebo- controlled, Multicenter, phase III study comparing the activity of Paclitaxel plus Trastuzumab Plus Lapatinib to Paclitaxel plus Trastuzumab plus placebo in Women with ErbB2 Overexpressing Metastatic Breast Cancer. (GSK)
8. Protocol : STUDY CODE protocol 0601- A Randomised ,controlled phase III TRIAL OF Picoplatin and Best Supportive Care (BSC) versus Best Supportive Care (BSC) alone in Small cell lung cancer (SCLC), Refractory or progressive within Six Months of completing First–Line , Platinum –Containing Chemotherapy.(PONIARD –SIRO)

9. Study Protocol: To study safety and efficacy of Recombinant Granulocyte colony Stimulating Factor –rG-CSF (ReliGrast™) in patients with chemotherapy induced neutropenia. –6 enrollments

10. Protocol(TR01-202) :- Phase–II Study of SLIT™ Cisplatin by Inhalation in the Treatment of Patients with Bronchoalveolar Carcinoma –1 enrollment

11. PROTOCOL: IPL-IBT-P01-PMS/AB A Post Marketing Surveillance Study to Assess the Safety of Neukine (G-CSF) in the Treatment & Prevention of Chemotherapy induced Neutropenia.-28 enrollment

12. Study Protocol: -Prospective Registry of Cancer & Events Involving Venous Thromboembolism. as co –investigator with Principle investigator – Dr. Rajiv Parakh

13. “STUDY PROTOCOLXRP6976J/3501: Multicenter, Open Label, Randomized. Phase III Trial comparing Immediate Adjuvant Hormonal therapy (ELEGARD- leuprolide acetate) in combination with TAXOTERE (docetaxel) Administered Every Three Weeks Versus Hormonal therapy Followed By the same therapeutic options in patients with Prostate cancer at High Risk of Relapse After Radical Prostatectomy.”

14. STUDY PROTOCOL:IPL-IBT-VMCP-T -: An Evaluation of safety & efficacy of VMCP plus Thalidomide in newly diagnosed patients of multiple Myeloma A Prospective, Non – comparative, Open label, Multicentric Study.

15. Protocol: BSV/AMBE II/ 0405 " Prospective, Multicentric, Open - Label, Phase II Study to Assess Efficacy And Safety Of Daily Intravenous Administration of Amphomul (Amphotericin B Emulsion) In Cancer Subjects With Febrile Neutropenia."

16. Protocol: Autologous Stem Cell Transplantation in Imatinib Relapsed Chronic Myeloid Leukemia Patients

17. Assisted in Cell based allogenic tumor specific therapy –experimental therapy using d-slim injection in advanced lung cancer

18. Protocol: EPO – ANE – 3010/Amendment INT – 5 - “A randomized, open label, Multicenter, phase 3 study of Epoetin Alfa plus Standard Supportive Care versus Standard Supportive Care in anemic Patients With Metastatic Breast cancer Receiving first-Line Standard Chemotherapy.”
19. Study number - EFC 6596A Randomized, open Label Multi-Center Study of Single Agent Larotaxel (XRP9881) at 90 mg/m² every 3 weeks Compared to continuous Administration of 5-FU For The Treatment of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine Containing Regimen
20. Protocol: 9238IL/0064: A Randomised, Double - Blind, Parallel - Group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg in Post menopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing after Previous Endocrine Therapy.
21. PROTOCOL: AN OPEN –LABEL PROSPECTIVE MULTICENTERIC STUDY TO ASSESS SAFETY AND EFFICACY OF BIOMAb-EGFR™ (Nimotuzumab) IN COMBINATION WITH CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH STAGE IIIB/IV NON SMALL CELL LUNG CANCER (NSCLC).
22. Protocol: Phase III study of Vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in patients with unresectable, locally recurrent or Metastatic breast cancer after prior anthracycline based adjuvant chemotherapy

11. ACHIEVEMENTS: -

1. Initiated Bone Marrow Transplantation at Sir Ganga Ram Hospital.
2. Chairperson National Cancer Foundation- a Charitable non-govt. Organization.

12. CONFERENCES ORGANISED:

- a) Update in Oncology I: Focus on Breast Cancer and Ovarian Cancer March 1998 Sir Ganga Ram Hospital, Delhi.

- b) Update in Oncology II: Focus on hematological malignancies and bone marrow transplantation January 1999, Sir Ganga Ram Hospital, Delhi.
- c) Update in Oncology III: Focus on lung cancer December, 1999 Sir Ganga Ram Hospital in collaboration with Delhi Medical Association.
- d) Update in Oncology IV: New development in cancer therapy 2001.
- e) Update in Oncology V: Concomitant CT-RT in Solid cancer 2002
- f) Update in Oncology VI: Adjuvant therapy in breast cancer 2003
- g) Update in Oncology VII: New horizons in hematologic cancer 2004
- h) Update in Oncology VIII: Fungal infections in immune Compromise patients 2005
- i) Update in Oncology IX: Adjuvant therapy of breast cancer. in Hotel Shangrila ,New Delhi 2007

13. Lectures Delivered / Chaired & Conferences attended:

1. Delivered a guest lecture in Cuttack AROI, in 1999 on Role of Interferon's in low grade lymphomas
2. Attended Asia Pacific Cancer conference in Penang Malaysia in 1999.
3. Attended ISMPO conference in Indore 1999.
4. Chaired a session on Nasal and Paranasal Sinuses Malignancy in Delhi in Conference organized by All India Rhinology Association on 20th July.
5. Delivered a guest lecture on Neutropenic fever in conference organized by RGCRI, Delhi, 2000.
6. Attended ASCO meeting in Atlanta in 2000.

7. Delivered a guest lecture on Management of low Grade Lymphomas in PGI Chandigarh in CME organized in 2000.
8. Attended annual Colo – rectal cancer conference in Barcelona Spain 2000.
9. Attended Elilily annual update in Koatkinabalu, Malaysia, 2001.
10. Delivered a guest lecture in Muzzafarnagar 2001, on Advances in Medical Oncology
11. Delivered a guest lecture in Mumbai Indian Society of Oncology Conference in Nov., 2002, on Role of Aromatase inhibitors in breast cancer
12. Delivered a guest lecture on –Role of liposomal doxorubicin in advanced ovarian cancer in 2001, August at Ludhiana Conference organized by Indian Gyaenocology Oncology Association.
13. Delivered a lecture on Sequencing of new agents in Colo- rectal cancer in Cochin in September 2001.
14. Delivered a lecture on Role of Gemcitabine in Urinary Bladder cancer in PGI, CHD in March 2001.
15. Attended ESMO conference held in Hamburg, Germany in October 2001.
16. Chaired a session on Role of anthracyclines in management of ovarian cancer in conference organized by RGCRI 2001.
17. Delivered a guest lecture on advances in the chemotherapy of cancers in Ghaziabad, 2001.
18. Attended ASH meeting in Orlando, Florida in 2001.
19. Attended ASCO meeting in New Orleans in 2001.
20. Attended update meet on Herceptin & Xeloda in Montreana Switzerland in February 2002.
21. Delivered ‘ Hira Lal Oration in Meerut – Recent advances in the management of hematological malignancies in 2002.

22. Attended a meeting in Goa on Temozolamide and Brain tumor in August 2002.
23. Delivered a lecture on the role of Interferons in CML at Jaipur in the conference organized by Rajasthan cancer Society in Sept 2002.
24. Delivered a guest lecture in Manila in Annual conference of Philippines Society of Oncology in 2002 on “ Quality of life issues after breast cancer”.
25. Delivered a lecture on annual P& R hospital Delhi, meet on Monoclonal antibodies in 2002.
26. Attended Advances in gastric cancer meeting in Jen, S. Korea, August 2002.
27. Participated in debate on – Use of Imatinib as first line therapy in CML in evidence based medicine programme organized by Tata Memorial Hospital Mumbai in Feb 2003.
28. Delivered a lecture on the role of concomitant chemotherapy and radiotherapy in cancer cervix at Jaipur in the conference organized by Gynaecology Oncology association of India in March 2003.
29. Delivered a lecture on Role of Erythropoietin in – CME on hematological disorders organized by Tata Memorial Hospital Mumbai in Feb 2003.
30. Attended ESMO conference held in Nice, France in October 2003.
31. Delivered guest lecture in Jolly Grant Medical College Dehradun, on – advances in medical oncology, in May 2003.
32. Delivered guest lecture on Management of advanced NSCLC in Meerut
33. Delivered guest lecture on Medical Oncology in the New Millenium in Meerut
34. Delivered guest lecture in Bhiwani on Role adjuvant therapy in Malignancies
35. Delivered a guest lecture in Ambala on Chemotherapy of Cancer
36. Delivered a guest lecture in Hissar on Advances in Chemotherapy of malignancy

37. Chaired a session on Role of CT- RT in Oesophageal cancer in SGRH, endo Oncology meeting in Delhi 2003.
38. Chaired a session 'Role of Induction Chemotherapy in Gynae Neoplasmas at Apollo hospital, April 2003 in Delhi.
39. Delivered lecture in association of Physicians of Meerut, meet on Management of Advanced Lung cancer in July 2003.
40. Attended a meeting in Mumbai on Taxotere & Lung cancer in June 2003.
41. Delivered a lecture on Role of G-CSF in cancer chemotherapy in Dr. Reddy's annual meeting in September 2003.
42. Delivered a lecture on – Clinical decisions in CML in Imatinib Era in launch of imatinib by Intas Oncology in October 2003 in Delhi.
43. Delivered a lecture in Aventis meet at Cochin on Role of new combinations in advanced breast cancer in August 2003.
44. Delivered a guest lecture on Role of aromatase inhibitors in adjuvant therapy of breast cancer in conference organized by RGCRI, Delhi 2003.
45. Delivered a guest lecture in DMC Ludhiana on New Drugs in the management of advanced colorectal cancer.
46. Delivered a guest lecture in ISO, Hyderabad on New drugs in the management of advanced colorectal cancer
47. Chaired a session and or delivered a lecture in the launch meeting of following drugs: liposomal doxorubicin, letrozole, rituximab,
48. Delivered a guest lecture: Letrozole as neoadjuvant in breast cancer in Novartis educational symposium in Ludhiana, August 2003.
49. Delivered a guest lecture: Letrozole in advanced breast cancer in Novartis educational symposium in Delhi September 2003.
50. Organised cancer detection camps at SGRH, Farrukhabad, Karnal.
51. Delivered a lecture on 'Long term Sequale of cancer Treatment in Adults at Dharmashila Cancer Hospital, conference in September 2002.

52. Delivered a lecture on 'Role of concomitant CT- RT in Oesophageal Cancer' in annual R&R hospital Delhi in 2003.
53. Panelist on the session ' New methods in cancer management ' of Dharmshila Cancer Hospital, conference in September 2003.
54. Delivered a lecture: 'Chemotherapy & hormone Therapy in Breast Cancer' in Regional Conference On Cancer in Saharanpur, March 2004.
55. ICH-GCP trained by GSK held at Taj Palace in May 2006
56. Attended the 4 th European Society of Oncology conference in Spain in June 2006
57. ON GOING.....

Site address: Room No. 212A, Department of Medical Oncology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi 60.

Signature:

Date:

DR. SHYAM AGGARWAL
Senior Consultant, H.O.D, Medical Oncology
Sir Ganga Ram Hospital